Want to see SE:SUS full AI Analyst Report?
SUS Stock Chart & Stats
kr30.84
kr0.26(0.80%)
At close: 4:00 PM EDT
kr30.84
kr0.26(0.80%)
Day’s Range― - ―
52-Week Rangekr23.70 - kr114.90
Previous CloseN/A
Volume30.20K
Average Volume (3M)1.61M
Market Cap
kr1.76B
Enterprise Valuekr884.60
Total Cash (Recent Filing)kr667.73M
Total Debt (Recent Filing)kr2.15M
Price to Earnings (P/E)33.6
Beta0.68
Next Earnings
Aug 19, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.03
Shares Outstanding51,026,237
10 Day Avg. Volume583,608
30 Day Avg. Volume1,614,194
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.39
Price to Sales (P/S)1.67
P/FCF Ratio24.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr45.00Price Target Upside45.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.92
Revenue Forecast (FY)kr986.35M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetThe company's exceptionally conservative balance sheet — near-zero debt (debt-to-equity ~0.0004) and net cash (SEK 668m) — provides durable financial flexibility. This lowers solvency risk, funds capex and R&D, and allows the firm to absorb industry or FX shocks without needing external financing, supporting longer-term strategic initiatives and operational resilience.
Cash Generation & FCF ReboundSurgical Science shows positive cash generation with TTM operating cash flow (~150M) and free cash flow (~102M), plus Q1 operating cash SEK 65m. Reliable FCF supports internal funding for production scaling (new Tel Aviv facility), product development, and working-capital needs, reducing reliance on external capital and enabling durable reinvestment in growth drivers.
Diversifying Robotics & Product PipelineManagement reports that license revenue is expanding beyond a single incumbent and the company is developing solutions for most of the top-20 robotics firms. Broadening the robotics customer base and launching products (ultrasound, shared platform modules) reduce customer-concentration risk and create recurring license and services opportunities that can sustain growth as robotic procedures proliferate.
Bears Say
Material FX ExposureAbout 70% of revenues are USD-denominated, so currency swings exert a durable influence on reported top-line and margins. Recent USD weakness cut reported sales and trimmed gross margin by ~2.2 percentage points. Persistent FX volatility can meaningfully depress reported profitability and cash flows across multiple quarters, complicating forecasting and margin management.
Intuitive License ReversionManagement quantified a SEK 60–90m 2026 license revenue headwind from a contractual reversion with Intuitive. This is a material, structural revenue reduction for 2026 that will lower recurring license income and compress margins until alternative customers or contracts scale to replace the shortfall, making near-term performance contingent on successful customer diversification.
China & APAC Structural ChallengesAPAC revenue fell ~25% with China identified as a structural drag as local manufacturers receive government support. This creates a durable competitive disadvantage that may require meaningful local investment or partnerships to address. Expect slower growth and pressured margins in the region until market positioning is adjusted and local competition dynamics evolve.
Surgical Science Sweden AB News
SUS FAQ
What was Surgical Science Sweden AB’s price range in the past 12 months?
Surgical Science Sweden AB lowest stock price was kr23.70 and its highest was kr114.90 in the past 12 months.
What is Surgical Science Sweden AB’s market cap?
Surgical Science Sweden AB’s market cap is kr1.76B.
When is Surgical Science Sweden AB’s upcoming earnings report date?
Surgical Science Sweden AB’s upcoming earnings report date is Aug 19, 2026 which is in 10 days.
How were Surgical Science Sweden AB’s earnings last quarter?
Surgical Science Sweden AB released its earnings results on May 20, 2026. The company reported kr0.37 earnings per share for the quarter, beating the consensus estimate of kr0.305 by kr0.065.
Is Surgical Science Sweden AB overvalued?
According to Wall Street analysts Surgical Science Sweden AB’s price is currently Undervalued.
Does Surgical Science Sweden AB pay dividends?
Surgical Science Sweden AB does not currently pay dividends.
What is Surgical Science Sweden AB’s EPS estimate?
Surgical Science Sweden AB’s EPS estimate is 0.4.
How many shares outstanding does Surgical Science Sweden AB have?
Surgical Science Sweden AB has 51,026,237 shares outstanding.
What happened to Surgical Science Sweden AB’s price movement after its last earnings report?
Surgical Science Sweden AB reported an EPS of kr0.37 in its last earnings report, beating expectations of kr0.305. Following the earnings report the stock price went up 12.785%.
Which hedge fund is a major shareholder of Surgical Science Sweden AB?
Currently, no hedge funds are holding shares in SE:SUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Surgical Science Sweden AB
Surgical Science Sweden AB (publ) specializes in the creation and distribution of virtual reality (VR) simulation platforms designed for evidence-backed training in laparoscopic and endoscopic procedures. Among its key offerings is the LapSim training system, which includes LapSim ST, tailored for educating surgical technologists and assistants, as well as LapSim essence, a compact and readily deployable VR simulator. The company's product portfolio further extends to the EndoSim system, a dedicated endoscopy simulator for comprehensive medical training. It also features TeamSim, an innovative platform fostering inter-professional education by integrating surgical simulation with real-world team dynamics. Additionally, they provide the Simball Box, which delivers velocity feedback alongside instructional task videos demonstrating optimal techniques, alongside their well-known Simbionix and robotic surgery simulators. Established in 1999, Surgical Science AB maintains its headquarters in Gothenburg, Sweden.
SUS Stock 12 Month Forecast
Average Price Target
kr45.00
▲(45.91% Upside)
Technical Analysis
Senzime AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
Saniona AB
―
C-Rad AB Class B
―


